It is also approved for metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens, anti-vascular endothelial growth factor (VEGF) therapy and if KRAS wild-type, anti-epidermal growth factor receptor (EGFR) therapy [10]. Grothey et al. in a phase 3 trial for metastatic colorectal cancer compared regorafenib to placebo. Here, EGFR is linked to metastatic colorectal cancer.